In addition, Generali et al. and Chan et al. evaluated the changes in TIL subtypes in ER + BC patients before and after letrozole/exemestane treatment and found a reduction in Foxp3 + T cells and an increase in CD8 + T cell infiltration among AI responders [41, 95]. This evidence concerns the gene CD8A and breast cancer.